Browse

Claims

Search the graph by meaning. Each result carries its current verdict; open one to see its decomposition, provenance, and the reasoning behind the assessment.

1 claim

The IL-6-blocking monoclonal antibody ziltivekimab: its cardiovascular outcomes evidence (notably the ZEUS trial in CKD patients with elevated hsCRP), effects on inflammatory biomarkers such as hsCRP and IL-6, safety, and development status. Not for other IL-6 or anti-inflammatory agents unless directly compared with ziltivekimab.

The IL-6 inhibitor ziltivekimab did not reduce cardiovascular events in the ZEUS trial

VerifiedThe claim traces to reliable primary sources through a clear chain of evidence.constitution →empirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →Inflammation in atherosclerosis Atherosclerotic cardiovascular diseaseimportance · minorImportance 0.30, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

Contribute

If a claim here is wrong, or missing evidence, open it: every claim page carries its own entry for challenges, evidence, and corrections. If the graph is missing a claim entirely, propose it below. A proposal is reviewed on its merits; accepted claims are matched against the graph and enter it with their reasoning on record.